|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||22.12 - 22.54|
|52-week range||18.18 - 23.47|
|Beta (5Y monthly)||0.29|
|PE ratio (TTM)||17.49|
|Forward dividend & yield||0.99 (4.44%)|
|Ex-dividend date||19 May 2022|
|1y target est||N/A|
GSK-controlled company in talks with UN-backed body on generic manufacture of highly effective PrEP injection
Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.
Eli Lilly, Novo Nordisk, Merck, and Glaxo are part of Zacks Industry Outlook article.